ES2109260T3 - Eritrocitos transformados, procedimiento para prepararlos y su utilizacion en composiciones farmaceuticas. - Google Patents

Eritrocitos transformados, procedimiento para prepararlos y su utilizacion en composiciones farmaceuticas.

Info

Publication number
ES2109260T3
ES2109260T3 ES91401602T ES91401602T ES2109260T3 ES 2109260 T3 ES2109260 T3 ES 2109260T3 ES 91401602 T ES91401602 T ES 91401602T ES 91401602 T ES91401602 T ES 91401602T ES 2109260 T3 ES2109260 T3 ES 2109260T3
Authority
ES
Spain
Prior art keywords
prepare
procedure
pharmaceutical compositions
erythrocytes
transformed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91401602T
Other languages
English (en)
Inventor
Mauro Magnani
Luigia Rossi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EUROP COMMUNITIES
Original Assignee
EUROP COMMUNITIES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EUROP COMMUNITIES filed Critical EUROP COMMUNITIES
Application granted granted Critical
Publication of ES2109260T3 publication Critical patent/ES2109260T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

LA INVENCION SE REFIERE A COMPOSICIONES QUE COMPRENDEN ERITROCITOS TRANSFORMADOS QUE CONTIENEN COMPUESTOS FOSFORILADOS, QUE NO SE PRODUCEN DE FORMA NATURAL EN UN ORGANISMO HUMANO O ANIMAL, TENIENDO DICHOS COMPUESTOS LAS PROPIEDADES DE: CION DE LA TRANSCRIPTASA INVERSA, Y TOS. LAS COMPOSICIONES DE LA INVENCION SON UTILES PARA EL TRATAMIENTO DE PATOLOGIAS PRODUCIDAS POR LA INFECCION DE UN HUMANO O UN ANIMAL POR EL VIRUS DE TIPO ARN.
ES91401602T 1991-06-14 1991-06-14 Eritrocitos transformados, procedimiento para prepararlos y su utilizacion en composiciones farmaceuticas. Expired - Lifetime ES2109260T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91401602A EP0517986B1 (en) 1991-06-14 1991-06-14 Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ES2109260T3 true ES2109260T3 (es) 1998-01-16

Family

ID=8208584

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91401602T Expired - Lifetime ES2109260T3 (es) 1991-06-14 1991-06-14 Eritrocitos transformados, procedimiento para prepararlos y su utilizacion en composiciones farmaceuticas.

Country Status (10)

Country Link
US (1) US5753221A (es)
EP (1) EP0517986B1 (es)
JP (1) JPH06510742A (es)
AT (1) ATE157879T1 (es)
CA (1) CA2102619A1 (es)
DE (1) DE69127615T2 (es)
DK (1) DK0517986T3 (es)
ES (1) ES2109260T3 (es)
GR (1) GR3025488T3 (es)
WO (1) WO1992022306A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409710A (en) * 1993-04-20 1995-04-25 Endocon, Inc. Foam cell drug delivery
US6040297A (en) * 1994-07-15 2000-03-21 Biosearch Italia, S.P.A. Dinucleoside-5',5'-pyrophosphates
DE69732225T2 (de) * 1997-05-05 2005-06-23 Dideco S.R.L., Mirandola Verfahren zur Verkapselung von biologisch aktiven Stoffen in Erythrocyten und Gerät dafür
CA2332986C (en) 1998-05-26 2009-09-08 Lifecell Corporation Cryopreservation of human red blood cells
US20100040546A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US8211656B2 (en) 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
US20100042072A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US20110070154A1 (en) * 2008-08-13 2011-03-24 Hyde Roderick A Artificial cells
WO2010025322A2 (en) * 2008-08-28 2010-03-04 The Florida International University Board Of Trustees Magnetic nanodelivery of therapeutic agents across the blood brain barrier
AU2014348683B2 (en) 2013-11-18 2020-11-05 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
WO2015153102A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
WO2019126818A1 (en) 2017-12-23 2019-06-27 Rubius Therapeutics, Inc. Artificial antigen presenting cells and methods of use
RU2020132924A (ru) 2018-03-08 2022-04-11 Рубиус Терапьютикс, Инк. Терапевтические клеточные системы и способы лечения рака и инфекционных заболеваний
EP3958877A1 (en) 2019-04-26 2022-03-02 Rubius Therapeutics, Inc. Buffered compositions including enucleated erythroid cells
WO2020243006A1 (en) 2019-05-24 2020-12-03 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells
WO2021092052A1 (en) 2019-11-04 2021-05-14 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells using myo-inositol
CN114901804A (zh) 2019-11-04 2022-08-12 鲁比厄斯治疗法股份有限公司 使用牛磺酸或亚牛磺酸产生去核红系细胞的方法
WO2022150578A1 (en) 2021-01-08 2022-07-14 Rubius Therapeutics, Inc. Methods of treating a tumor in a human subject
WO2022150569A1 (en) 2021-01-08 2022-07-14 Rubius Therapeutics, Inc. METHODS OF INCREASING NKp30-POSITIVE LYMPHOCYTES IN A SUBJECT AND USES THEREOF
TW202304482A (zh) 2021-03-14 2023-02-01 美商盧比亞斯治療公司 於個體中增加nkg2d陽性淋巴球之方法及其用途
TW202317179A (zh) 2021-06-03 2023-05-01 美商盧比亞斯治療公司 在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2529463B1 (fr) * 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
IL86650A0 (en) * 1987-06-30 1988-11-30 Biophor Corp Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
FR2653561A1 (fr) * 1989-10-19 1991-04-26 Fondation Nale Transfusion San Hetero-anticorps anti-rhd et composition pharmaceutique les contenant.

Also Published As

Publication number Publication date
JPH06510742A (ja) 1994-12-01
DK0517986T3 (da) 1998-03-30
EP0517986A1 (en) 1992-12-16
DE69127615D1 (de) 1997-10-16
GR3025488T3 (en) 1998-02-27
EP0517986B1 (en) 1997-09-10
CA2102619A1 (en) 1992-12-15
ATE157879T1 (de) 1997-09-15
US5753221A (en) 1998-05-19
WO1992022306A1 (en) 1992-12-23
DE69127615T2 (de) 1998-03-19

Similar Documents

Publication Publication Date Title
ES2109260T3 (es) Eritrocitos transformados, procedimiento para prepararlos y su utilizacion en composiciones farmaceuticas.
ATE114113T1 (de) Verwendung von droloxifen bei der behandlung von knochenerkrankungen.
DK552684D0 (da) Desulfatohirudiner samt deres fremstilling og anvendelse
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
AR020662A1 (es) Compuestos dihidrotiazoles policiclicos, procedimientos para su preparacion, medicamento, procedimiento para la preparacion de dicho medicamento y lautilizacion de dichos compuestos para la preparacion de un medicamento.
TR200101649T2 (tr) Piperazin türevleri.
DE68929388D1 (de) Aus Harn isolierte antikoagulierende Verbindung
MX9202544A (es) Compuestos de diaminoftalimidas substituidas y analogas, procedimiento para su preparacion y preparados farmaceuticos que los contienen.
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
DE68924006T2 (de) Pharmazeutische Zusammensetzungen mit Eierschalenbestandteilen und ihre Herstellung und Verwendung.
EE200100125A (et) TAN-1057 derivaadid
BR0016430A (pt) Método para o tratamento e/ou prevenção da tosse em um animal de sangue quente, uso de um composto, composto, e, composição farmacêutica
DK418986D0 (da) Pyrrolobenzimidazoler, pyrrolobenzoxazoler og pyrrolobenzthiazoler, fremgangsmaader til fremstilling heraf og laegemidler med indhold heraf
MC1930A1 (fr) Produit antiviral
ATE141796T1 (de) 2',5'-oligoadenylat-derivate zur verwendung als heilmittel
ATE3552T1 (de) Verfahren zur herstellung von phosphono-hydroxy- essigsaeure und salzen derselben sowie diese enthaltende autivirale mittel.
FI902901A0 (fi) Dibenzol/1,5/dioxocin-5-one-derivat, deras anvaendning i laekemedel och foerfarande foer deras framstaellning.
PT91415A (pt) Processo para a preparacao de novos derivados de furiltiazol
BR0212719A (pt) Composto, método para produzir um composto, composição farmacêutica que compreende o mesmo, método para tratar uma enfermidade relacionada com os ossos em um paciente e sua utilização
ES2079539T4 (es) Inhibidores de la captacion de calcio.
ES508757A0 (es) "procedimiento para la preparacion de acidos antranilicos sustituidos con radicales basicos"
BR0016427A (pt) Método para o tratamento e/ou prevenção da tosse em um animal de sangue quente, uso de um composto, composto, e, composição farmacêutica
ATE74767T1 (de) Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.
DK0580624T3 (da) Hidtil ukendte cytarabinderivater, fremstilling og anvendelse deraf
DE3687895D1 (de) Arginin- und agmatinderivate zur behandlung von protozoen-infektionen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 517986

Country of ref document: ES